mimiX Biotherapeutics Ltd.

Swiss startup mimiX Biotherapeutics is revolutionizing the bioprinting skin product industry with a cutting-edge technology. FastSkin® tissue is an advanced dermal substitute for treating acute and chronic wounds, utilizing the unique biofabrication technique Sound Induced Morphogenesis (SIM).
SIM patterns biological materials like cells, organoids, or tissue fragments into 3D constructs for in vitro engineered tissues, enabling faster and more efficient multi-cellular assemblies. mimiX Biotherapeutics is seeking FDA clearance for FastSkin®, which could become the world's first acoustic cell patterning clinical product, marking a significant milestone for the industry.